Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis

Published:2021-12-31 Issue:1 Volume:54 Page:108-120
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Hung Hsuan-Yu¹,Hung Wei-Liang²,Shih Chia-Lung³^ORCID,Chen Chung-Yu⁴⁵⁶

Affiliation:

1. Department of Pharmacy, Ditmanson medical foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan

2. Division of Nephrology, Department of Medicine, Zouying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan

3. Clinical Medicine Research Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan

4. Master Program in Clinical Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

5. Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

6. Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2021.2012589

Reference23 articles.

1. Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

2. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV Genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.

3. Gane E, Poordad F, Zadeikis N, et al. Safety and pharmacokinetics of Glecaprevir/Pibrentasvir in adults with chronic Genotype 1-6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657–1664.

4. FDA. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. [cited 2021 May 12]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warnsabout-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and5.

5. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews 2021;10:89.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glecaprevir-Pibrentasvir and Ethinyl Estradiol-Induced Liver Injury in a Patient Without Cirrhosis;Cureus;2024-06-08

2. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

3. Polysaccharides from Chinese herbal medicine: a review on the hepatoprotective and molecular mechanism;Chinese Journal of Natural Medicines;2024-01

4. Discovery of a fused bicyclic derivative of 4-hydroxypyrrolidine and imidazolidinone as a new anti-HCV agent;Virology;2023-09

5. Safety considerations in the management of hepatitis C and HIV co-infection;Expert Opinion on Drug Safety;2023-04-27